« Back to Record
Kim, T. W., Burris, H. H., de Miguel Luken, M. J., Pishvaian, M. M., Bang, Y. J., Gordon, M., Awada, A., Camidge, D. R., Hodi, F. S., McArthur, G. A., Miller, W. W., Cervantes, A., Chow, L. Q. M. L., Lesokhin, A. A., Rutten, A., Sznol, M., Rishipathak, D., Chen, S. C., Stefanich, E., Pourmohamad, T., Anderson, M., Kim, J., Huseni, M., Rhee, I., & Siu, L. L. Y. L. (2022). First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors. Clinical cancer research, 28(16), 3452-3463. doi:10.1158/1078-0432.CCR-21-4020
Citation APA
Permalink
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/372584



